ArticleWorld journal of surgical oncology2026
Melittin enhances PD-L1 blockade in prostate cancer by inhibiting M2 macrophage polarization and recruitment.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe immunosuppressive tumor microenvironment (TME) limits the efficacy of immunotherapy in prostate cancer treatment. This study aims to investigate how melittin remodels the TME in prostate cancer and enhances the response mechanism to anti-PD-L1 therapy.
methodsThe antitumor efficacy of melittin was evaluated using subcutaneous and orthotopic prostate cancer mouse models, in vitro co-culture systems of prostate cancer cells (PC-3, 22RV1) and THP-1-derived macrophages, and validation in primary bone marrow-derived macrophages (BMDMs). RNA sequencing, flow cytometry, qPCR, Western blot, ELISA, Transwell migration assays, CCK-8 viability analysis, and immunohistochemistry were employed to explore the underlying mechanisms. The synergistic effect of melittin combined with anti-PD-L1 antibody was assessed in vivo.
resultsMelittin significantly inhibited tumor growth in vivo and remodeled the tumor immune microenvironment by increasing CD8⁺ T cell infiltration while reducing macrophage accumulation. Mechanistically, melittin suppressed M2 macrophage polarization through inhibition of the JAK–STAT pathway, as evidenced by reduced phosphorylation of JAK1 and STAT3—an effect partially reversed by the JAK–STAT agonist RO8191 and mimicked by the JAK inhibitor Ruxolitinib. Melittin also attenuated macrophage recruitment via downregulation of tumor-derived CCL2, thereby compromising the CCL2–CCR2 chemotactic axis. In both subcutaneous and orthotopic models, melittin combined with anti-PD-L1 antibody synergistically reduced tumor burden, suppressed PD-L1 expression, and enhanced CD8⁺ T cell infiltration. Notably, melittin did not directly regulate PD-L1 expression in tumor cells in vitro, suggesting that its effects on PD-L1 in vivo are mediated through modulation of the TME.
conclusionMelittin reverses the immunosuppressive TME in prostate cancer by inhibiting JAK-STAT mediated M2 polarization and CCL2-dependent macrophage recruitment. This reprogramming of the TME, combined with PD-L1 blockade, represents a potential combination immunotherapy strategy for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.